BIVI Historical PE Ratio Notes

— BioVie Inc. (ticker: BIVI) is a clinical-stage biopharmaceutical company focused primarily on developing innovative therapies for serious debilitating diseases, including Alzheimer’s disease and advanced liver conditions like hepatic encephalopathy. Because BioVie does not yet have any FDA-approved products or commercial revenue streams, its earnings profile is highly irregular, dominated by research & development expenses rather than income. As a result, historical P/E ratio charts for BIVI will either show extremely high, undefined, or even negative values, especially during periods of intensive clinical investment and lack of reported earnings. This is typical for early-stage biotech firms, where investor sentiment & valuation are driven more by clinical trial progress and regulatory developments than by traditional measures such as earnings. When analyzing BIVI’s historical price, earnings, and P/E ratios, it’s crucial to factor in that the company’s numbers reflect ongoing investment in long-term drug development pipelines, rather than profitability. Investors should therefore be cautious about drawing direct conclusions from standard valuation metrics like the P/E ratio alone, instead considering additional factors such as pipeline status, upcoming catalysts, and cash runway.

On this page we presented the BIVI Historical PE Ratio information for BioVie' stock. The average BIVI historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average BIVI historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this BIVI historical PE result, against the recent PE: when this page was posted on 5/19/2026, the most recent closing price for BIVI had been 1.31, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on BIVI or any other given stock, valuation analysis for BIVI can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate BioVie PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for BIVI. Thanks for visiting, and the next time you need to research BIVI Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.